New River Provides Preclinical Test Results on NRP290

New River Pharmaceuticals has provided an update on its pipeline, including results from preclinical testing on the company's second compound under development, NRP290, a hydrocodone derivative for the treatment of pain.

Data have shown that the bioavailability of hydrocodone and hydromorphone levels in NRP290 when taken orally was comparable to hydrocodone bitartrate in dogs, but that there was reduced bioavailability of hydrocodone and hydromorphone at increasing doses of NRP290 when taken orally.

The data also indicated that NRP290 had reduced bioavailability when taken by intranasal and intravenous routes, and resisted chemical and enzymatic extraction techniques. The company also identified further preclinical research efforts using the company's proprietary Carrierwave technology in the treatment of hypothyroidism and inflammation.